Myasthenia Gravis Disease Market
The surging cases of neuromuscular disorders are estimated to favor the market growth globally. Myasthenia gravis is referred to as a neuromuscular disorder which results in the skeletal muscles to weaken.
The Myasthenia Gravis Disease Market Share is projected to reach USD 1.97 billion by 2032 at 7.9% CAGR during the forecast period 2023-2032.
The disease generally occurs due to the impairment of communication between the nerve cells and the muscles and causes difficulty in the relaxation and contraction of muscles. The antibodies present in the body destroy the receptor for acetylcholine at the neuromuscular joint which prevents the muscles from contracting and performing its normal function.
Major Key Players:
Leading Key Market Players are Fresenius Kabi, GSK plc, AbbVie Inc., Biogen Inc., Bristol-Myers Squibb Co., F. Hoffman-La Roche Ltd., Cipla, RPG Life Sciences, Teva Pharmaceutical Industries Ltd., Apotex Corporation, Novartis, Piramal Healthcare, Sun Pharmaceuticals Industries Ltd., and Valeant.
Segment Analysis
The global Myasthenia Gravis Disease Market Outlook on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the global myasthenia gravis disease market can be segmented into imaging, blood tests, electrodiagnostic, edrophonium tests, pulmonary function tests, and others. The imaging segment is classified into X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and others.
On the basis of treatment, the global myasthenia gravis disease market can be segmented into medication, surgery, autologous hematopoietic stem cell transplantation (HSCT), plasmapheresis and intravenous immunoglobulin, and others. By medication, the market is divided into acetylcholinesterase inhibitors, immunosuppressants, steroids, and others. The acetylcholinesterase inhibitors segment is further classified into atropine, neostigmine, pyridostigmine, and others. Immunosuppressant drugs are further divided into azathioprine, mycophenolate mofetil, tacrolimus, and rituximab. The steroids segment is further divided into prednisone and others. Surgery is divided into thymectomy and others.
On the basis of end user, the global myasthenia gravis disease market is segmented into hospitals, clinics, academic research institutes, and others.
Regional Analysis
The global myasthenia gravis disease market is expected to be dominated by North America over the forecast period, with the Americas segment holding the dominant share in the market. The Americas market for myasthenia gravis disease is mainly driven by the growing awareness about the disease, as neurological diseases have been studied in detail in the region and awareness about this kind of disease is significantly high in the region. The growing demand for effective medications for neuromuscular diseases such as myasthenia gravis is likely to drive the drug development scenario in the Americas region over the forecast period, leading to steady growth of the myasthenia gravis disease market.
Europe holds the second largest share in the global myasthenia gravis disease market and is likely to remain a leading contender in the global market over the forecast period due to the growing awareness about neuromuscular conditions. Myasthenia gravis holds a significant position in the Europe market, as the disease can cause a significant burden on national healthcare systems. The increasing financial burden of myasthenia gravis disease is likely to drive the myasthenia gravis disease market in Europe over the forecast period.
Asia Pacific is likely to be a major regional market for myasthenia gravis disease over the forecast period due to the growing awareness about the disease and the increasing desire to eliminate the disease from urban populations in growing economies such as China, India, Japan, and South Korea. Increasing healthcare expenditure in the region is likely to be a major driver for the myasthenia gravis disease market over the forecast period. Rising awareness about neuromuscular diseases is likely to be a key driver for the myasthenia gravis disease market in Asia Pacific over the forecast period.
About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 646 845 9312